Orserdu
Payments companies reported to CMS as associated with Orserdu. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Orserdu, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Orserdu
These are the largest totals companies reported as associated with Orserdu. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Anne Odea | Westwood, KS | Medical Oncology | $293,090.30 |
| Fengting Yan | Seattle, WA | Hematology & Oncology | $183,618.06 |
| Michel Velez | Orlando, FL | Medical Oncology | $118,867.12 |
| Rena Callahan | Valencia, CA | Internal Medicine | $113,825.19 |
| Ricardo Alvarez | Houston, TX | Medical Oncology | $112,766.85 |
| Chaitali Nangia | Costa Mesa, CA | Hematology & Oncology | $107,301.16 |
| Andrew Seidman | New York, NY | Medical Oncology | $98,114.54 |
| Amy Krie | Minneapolis, MN | Medical Oncology | $93,471.05 |
| Jules Cohen | Stony Brook, NY | Hematology & Oncology | $93,149.18 |
| Vijayakrishna Gadi | Seattle, WA | Medical Oncology | $87,006.14 |
Prescribed Orserdu?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.